Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition

The deal "provides entry into the exciting field of protein degradation, a fast-growing area of cancer drug research that is attracting substantial interest from some of the world’s largest pharmaceutical companies because of the potential advantages of protein degraders, including the ability to go after previously undruggable cancer-promoting targets," said David Arthur, CEO of Salarius.